DMAC News and Press, DiaMedica Therapeutics Inc. From 11/24/20

Gainers: Sundial Growers (SNDL) +36%, DiaMedica Therapeutics (DMAC) +20%, Aurora Cannabis ACB +19%, Lyra Therapeutics (LYRA) +19%, Tilray TLRY +10%.Losers: Medigus (MDGS) -17%, Graybug Vision (GRAY) -14%, Immunic (IMUX) -13%,&#x...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders, is pleased to announce that Rick Pauls, President and CEO of DiaMedica, will participate in a fireside ch...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological disorders, today announced its President and CEO, Rick Pauls, and Chief Financial Officer, Scott Kellen, are scheduled to parti...

DiaMedica Therapeutics Inc. (DMAC) Q3 2020 Earnings Conference Call Nov 05, 2020, 08:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake...

The following slide deck was published by DiaMedica Therapeutics Inc. in conjunction with their 2020 Q3 earnings call. For further details see: DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

DiaMedica Therapeutics (DMAC): Q3 GAAP EPS of -$0.19 misses by $0.04.Cash and cash equivalents of $9.8M.Press Release For further details see: DiaMedica Therapeutics EPS misses by $0.04

Diabetic Kidney Disease Cohort Added to REDUX Study, Near Fully Enrolled FDA Grants Meeting Request for Review of Planned Stroke Study Program Completed $23M Public Offering of Common Shares Conference Call with Management Tomorrow, November 5, ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, November 4 th . DiaMedica will host a live conference call on Thursday, November 5 th at 7:00 AM Central Time to discus...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4 th Annual Best Ideas Growth (BIG4) Conference, being held on Thursday, September 17, 2020, on a virtual platform. DiaMedica Therapeutics management is ...

DiaMedica Therapeutics ( DMAC +4.2% ) announced dosing of the first participants in the diabetic kidney disease cohort of the REDUX Phase II Chronic Kidney Disease study. More news on: DiaMedica Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...